Additionally, preclinical studies have shown that a single 30-MBq dose of Cu-67 SAR-bisPSMA can achieve tumor control for up to 6 weeks [114], suggesting robust anti-tumor activity and highlighting sarcophagine chelators as a promising tool in PSMA-based theranostics. The gene discussed is FOLH1; the disease is neoplasm.